Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 13 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (2)
P 1 (2)
P 2 (7)

Trial Status

Not Yet Recruiting4
Recruiting3
Unknown3
Completed2
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07405736Phase 2Not Yet Recruiting

Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer

NCT07349043Phase 1RecruitingPrimary

A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer

NCT07241715Phase 2Not Yet Recruiting

Conversion Surgery for Gastric Cancer With Peritoneal Metastases (CONVERGENCE)

NCT07107633Phase 2Recruiting

A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.

NCT06957782Not ApplicableNot Yet RecruitingPrimary

The Value of 68Ga-FAPI PET/CT for Evaluating Peritoneal Treatment Response

NCT06940921Phase 1Active Not Recruiting

SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases

NCT06914687Phase 2Not Yet Recruiting

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

NCT06597526RecruitingPrimary

The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.

NCT06102278CompletedPrimary

ML Models for Predicting Postoperative Peritoneal Metastasis After Hepatocellular Carcinoma Rupture

NCT05544253Phase 2Unknown

Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC

NCT02779608Phase 2Unknown

The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant Ascites

NCT02591667Phase 2Unknown

Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer

NCT01242436Not ApplicableCompleted

Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis

Showing all 13 trials

Research Network

Activity Timeline